Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily make copies of Novo Nordisk’s semaglutide. The gambit boosted the telehealth firm’s stock price, and executives made millions selling shares.
READ SOURCE
